•Experimental crystal and spectral characteristics of BICT and MNPBICT were studied.•In silico drug likeness screening using Swiss ADME online server were carried out.•Bacterial DNA gyrase inhibitory ...studies were carried out by molecular docking method.•The in vitro analysis explored the promising antibacterial activity of derivative MNPBICT and could be considered as an antibacterial lead compound.
The crystal, spectral characteristics and antibacterial activityof two benzogindazole fused carbothioamide derivatives are explained in this study. The structural characterization of our compounds 3-(4-methylphenyl)-N-phenyl-3,3a,4,5-tetrahydro-2H-benzogindazole-2-carbothioamide (BICT) and 3‐(4‐methoxyphenyl)‐N‐(4‐nitrophenyl)‐ 3,3a,4,5-tetrahydro-2H-benzogindazole-2-carbothioamide (MNPBICT) using SCXRD technique is reported. The crystal structures of our derivatives are substantiated with 1H, 13C NMR and FTIR spectral methods. For the synthesized compounds, in silico drug likeness screening using SwissADME online server and DNA gyrase inhibition activity through molecular docking studies (PDB ID: 1KZN) with bacterial protein are reported. The antibacterial activity of our compounds are tested against S. Aureus, B. megaterium, P. Aeroginosa and E. coli bacterial strains by disk broth dilution method. From the in silico pharmacological screening and docking results, it is found that our compound MNPBICT possess higher druggable nature and are effective DNA gyrase inhibitor against protein 1KZN compared to BICT and drug ciprofloxacin. The in vitro analysis explored the promising antibacterial activity of derivative MNPBICT and could be considered as a lead compounds for antibacterial drug design.
Two novel compounds 1‐(5‐4‐fluorophenyl‐3‐phenyl‐4,5‐dihydro‐1H‐pyrazol‐1‐yl)‐2‐thiocyanatoethanone (FSCN) and 1‐(5‐4‐chlorophenyl‐3‐phenyl‐4,5‐dihydro‐1H‐pyrazol‐1‐yl)‐2‐thiocyanatoethanone (ClSCN) ...were synthesized and characterized by SC‐XRD, 1H NMR, 13C NMR, FTIR, and UV methods. The X‐ray diffraction studies were utilized to prove the 3D crystal structures of FSCN and ClSCN. In both the compounds, the packing is mostly driven by CH⋯N, CH⋯O, and CH⋯π (benzene ring as an acceptor) interactions. In ClSCN, additionally, the π⋯π interaction is observed between the pyrazole ring of one molecule and the benzene ring of the other molecule. The experimental values were compared with the results of DFT/B3LYP/6‐311G++(d,p) theoretical computations. The pharmacological screening for FSCN and ClSCN was performed using molinspiration and PreADMET web server. To analyze antibacterial inhibition of the synthesized ligands and Ciprofloxacin (control drug) were interacted with antibacterial protein Thymidylate Kinase (TMK) (PDB ID: 4QGG) with the help of AutoDock Vina tool. The ADMET and docking results of FSCN and ClSCN pointed out the better drug likeness nature and good inhibition behavior with TMK protein. The antibacterial in vitro studies suggested that FSCN compound inhibited well with antibacterial strains than that of ClSCN. The current investigation suggests that with further improvements, our compounds could be preferred as substitute medicine for bacterial diseases.
Antibacterial activity of newly synthesized pyrazoline fused thiocyanatoethanone derivatives as thymidylate kinase inhibitors.
